Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
128
resultados
Última actualización
29/07/2025 [07:29:00]
Resultados 100 a 125 de 128
Resumen de: US2025177292A1
The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone.
Resumen de: US2025179031A1
Described herein are compounds, methods for making such compounds, and the use of such compounds in the treatment of cancer, an inflammatory disease or condition or neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and ALS.
Resumen de: WO2025117721A1
The present disclosure provides products and methods for facilitating brain lipid transport in a subject. In some aspects the products are useful for slowing the progression of or preventing the development of Alzheimer's Disease or for treating Alzheimer's disease. The products include reconstituted lipoprotein particles (rLPs). Libraries and screening of libraries to identify additional rLPs are also disclosed.
Resumen de: WO2025113506A1
The present invention relates to the field of biomedicine. Provided are a marker that can be used for early diagnosis of Alzheimer's disease, and the use thereof. Specifically provided is a marker for early diagnosis of Alzheimer's disease. The marker is a Maf1 gene or the protein thereof. High expression of the Maf1 gene or the protein thereof in neuronal cells indicates that a subject is at high risk of developing Alzheimer's disease. The method provides a new diagnostic and therapeutic target for AD.
Resumen de: US2025179065A1
Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.
Resumen de: US2025177351A1
The present invention is directed to methods of treating Alzheimer's disease in a subject in need thereof. Also disclosed are methods of identifying novel compounds that may be useful in the treatment and prevention of Alzheimer's disease. Also disclosed are methods of determining the Alzheimer's disease status of a subject.
Resumen de: EP4563154A1
Provided is a drug for treating Alzheimer's disease, the drug enabling retention of cognitive function amelioration and nerve quality improvement for a specific time even after treatment ends. This drug for causal treatment of Alzheimer's disease (disease-modifying drug) contains hydrogen gas as an active ingredient.
Resumen de: EP4563575A1
Disclosed are compounds having general formula I, a method for preparing same, a pharmaceutical composition thereof, and use thereof. Specifically, the present invention provides a compound having a structure represented by general formula I, and a racemate, an R-isomer, an S-isomer and a pharmaceutically acceptable salt thereof, or a mixture thereof. The compound has a good effect on promoting transcription factor EB (TFEB) nuclear translocation and promoting lysosome generation, and can be used for preventing, treating, or assisting in treating various diseases related to lysosome dysfunction and biosynthesis insufficiency, especially neurodegenerative diseases caused by the accumulation of intracerebral pathological proteins (e.g., β-amyloid protein and a-synuclein), such as Alzheimer's disease (AD) and Parkinson's disease (PD).
Resumen de: WO2024026061A1
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject is of therapeutic benefit, specifically in treating Huntington disease ("HD"). This disclosure also features a composition containing the same as well as methods of using and making the same.
Resumen de: MX2025005880A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: MX2025001992A
Benzazepine derivatives of Formula (I), compositions comprising therapeutically effective amounts of those benzazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders or associated with risk factors for cognitive impairment. In particular, it relates to the use of a αs-containing GABA<sub>A</sub> R agonist (e.g., a as-containing GABA<sub>A</sub> R positive allosteric modulator) in treating cognitive impairment associated with central nervous system (CNS) disorders or having a risk factor associated with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a as-containing GABA<sub>A</sub> R agonist (e.g., a as-containing GABA<sub>A</sub> R positive allosteric modulator) as described herein in treating brain c
Resumen de: MX2025003197A
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: MX2025000202A
The present invention relates to a pharmaceutical composition that contains sustained-release microspheres composed of semaglutide or a pharmacologically acceptable salt thereof, a bioavailability enhancer, and a biodegradable polymer and which is designed to avoid rapid initial drug release (initial burst), contain a high concentration of the drug relative to particle size, have high bioavailability, and minimize patient discomfort and inflammatory reactions when administered to the human body, whereby the composition is useful in the prevention or treatment of diabetes, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, or degenerative neurological diseases such as Alzheimer's and Parkinson's disease and in the preservation of beta-cell functions.
Resumen de: AU2023367284A1
Applicant discloses methods and compositions for treating a patient suffering from amyotrophic lateral sclerosis (ALS) comprising administration of a heteroaryl ketone fused azadecalin compound. In embodiments, the heteroaryl ketone fused azadecalin compound is dazucorilant: (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl) sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo3,4-gisoquinolin-4a-yl) (pyridin-2-yl)methanone, having the chemical structure illustrated as. Suitable doses include daily administration of 150 milligrams and 300 milligrams of dazucorilant. Suitable doses include daily administration of dazucorilant with food, or with water, or with food and water. Daily administration of dazucorilant is effective to increase dazucorilant exposure up to about 2-fold when continued for seven days or more. Administration of such a heteroaryl ketone fused azadecalin compound may comprise oral administration, enteral administration, or other administration. Pharmaceutical compositions comprising dazucorilant are useful in the treatment of patients suffering from ALS. Suitable pharmaceutical compositions comprising dazucorilant include, e.g., pharmaceutical compositions for oral administration and pharmaceutical compositions for enteral administration.
Resumen de: CN120053602A
The invention belongs to the technical field of biological medicines, and particularly relates to application of a sialic acid transporter (Sialin) or a reagent targeting a Sialin protein Gln325 site in preparation of a medicine for treating the Alzheimer's disease. The invention finds that the Sialin protein or the Gln325 site of the Sialin protein can be used as a therapeutic target for treating the Alzheimer's disease, and tests find that overexpression of the Sialin protein can improve various characteristic pathologies of cognitive impairment, myelin sheath reduction and A beta increase of the Alzheimer's disease. Therefore, not only is a new function of the Sialin protein found, but also an accurate target spot capable of treating the Alzheimer's disease is found, and an important technical support is provided for treatment of the Alzheimer's disease and drug development.
Resumen de: CN120053658A
The invention discloses a preparation of a natriuretic peptide signal channel. The preparation maintains the metabolite content of natriuretic peptide in vivo at a normal level. The invention also discloses an application of a medicine taking the brain natriuretic peptide or the related receptor thereof as an action target spot in preparation of a medicine for treating Alzheimer's disease or social disorder related diseases. According to the preparation of the natriuretic peptide signal channel, diseases such as Alzheimer's disease and social disorder are treated or relieved through specific action targets of the BNP or related receptors thereof, a new treatment target and a nerve regulation and control treatment strategy are provided for treating the diseases such as AD, and the preparation has a wide application prospect.
Resumen de: WO2025110663A1
Disclosed is a percutaneous absorption preparation containing donepezil that is a pharmacologically active substance useful in treating Alzheimer's dementia symptoms. This percutaneous absorption preparation suppresses donepezil drug crystallization in the percutaneous absorption preparation even when left at room temperature for a long period of time, can improve a percutaneous permeability degree (cumulative permeation amount and skin permeation rate) of the drug, and in particular, can significantly increase the drug absorption of donepezil despite of a small drug loading amount compared to the currently commercially available Donerion patch.
Resumen de: CN120060371A
The invention discloses a magnetic genetics system based on a clMagR gene and application of the magnetic genetics system in Parkinson's disease. The invention aims to inject the clMagR gene into neurons through an adeno-associated virus (AAV) vector, and regulate and control the biological functions of cells or tissues in combination with exogenous iron and a magnetic field stimulation technology. Compared with optogenetics, the system has the advantages that optical fiber implantation and light source direct irradiation required by optogenetics are avoided through accurate control of an external magnetic field, the risk of invasive surgery is reduced, and the cell function of a deep nerve area, especially a deep brain area, can be more widely regulated in vivo. Compared with a traditional treatment method, the invention discloses a non-invasive and adjustable gene treatment strategy, provides a new technical normal form for the fields of stem cell treatment, nerve regeneration, drug delivery, illumination of a neural circuit mechanism of diseases and the like, and has relatively high application potential and wide preclinical research value.
Resumen de: CN120053483A
According to the method, the chiral gold nanoparticles with good biocompatibility are successfully prepared by finely controlling chemical reaction conditions. Meanwhile, a C57BL/6 adult mouse is selected as an experimental subject, excitatory neurotoxin quinolinic acid is injected into a specific area of the brain of the mouse by adopting a stereotactic injection technology, and the Huntington's mouse model is successfully established. On the basis, the synthesized chiral gold nanoparticles are administered in an intravenous injection mode, and a PBS group and a tetrabenazine group are set as contrasts, so that the treatment effect of the chiral gold nanoparticles is evaluated. The prepared chiral gold nanoparticles can improve the structure of the cerebellum tissue of a mouse and relieve neurodegenerative diseases, a new thought and method are provided for treatment of the Huntington's disease, and the chiral gold nanoparticles have wide application prospects.
Resumen de: CN120076808A
The present disclosure relates to a dual orexin receptor antagonist, i.e., Labobolifera, as well as compositions and methods for use in the treatment of Alzheimer's disease (AD), e.g., in a subject suffering from or at risk of developing AD.
Resumen de: NZ786051A
The present invention relates to the compounds of formula (I) that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (a-synuclein, A- synuciein, aSynuciein, A-syn, a-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson’s disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.
Resumen de: NZ772066A
This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAAreceptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer’s Disease(AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson’s disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an α5-containing GABAAreceptor agonist (e.g., an α5-containing GABAAreceptor positive allosteric modulator) in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.
Resumen de: CN120058593A
The invention relates to a donepezil derivative and application thereof in drugs, in particular to a compound which is a compound shown in a formula I or a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug of the compound shown in the formula I, the compound can play a long-acting role in inhibiting the expression of acetylcholinesterase, so that the Alzheimer's disease can be prevented and/or treated for a longer time. # imgabs0 #
Resumen de: CN120053687A
The invention discloses a nano vesicle and a cytoskeleton for treating Parkinson's disease, and belongs to the field of Parkinson's disease transplantation therapy, and the preparation method comprises the following steps: 1, mixing a drug solution and a micelle solution at 0-4 DEG C to form a mixed solution, putting the mixed solution into a rotary evaporator, and carrying out rotary evaporation to remove dimethyl sulfoxide so as to obtain a drug-loaded micelle; 2, adopting a cell nano perforation technology, and selecting bv2 cells to obtain exosomes; and step 3, uniformly mixing and stirring the drug-loaded micelle and the exosome at the stirring speed of 200-300rpm, performing post-ultrasonic treatment, adding the mixture into a liposome extruder after the post-ultrasonic treatment, and extruding the mixed solution for 10-20 times to obtain the nano-vesicle for treating the Parkinson's disease. The nano-vesicle disclosed by the invention treats the Parkinson's disease by utilizing the synergistic effect of various effective components, has an active oxygen responsive intelligent drug release property, is high in targeting property, and has remarkable advantages and wide application prospects in the aspect of treatment of the Parkinson's disease.
Nº publicación: CN120077136A 30/05/2025
Solicitante:
GUANGZHOU BEBETTER MEDICINE CO LTD
\u5E7F\u5DDE\u5FC5\u8D1D\u7279\u533B\u836F\u80A1\u4EFD\u6709\u9650\u516C\u53F8
Resumen de: CN120077136A
According to the present invention, the siRNA and the polypeptide oligonucleotide drug for inhibiting the expression of the amyloid precursor protein (APP) gene in the human body cell, and the application thereof are provided, the siRNA has good APP expression inhibition activity, and can improve the target silencing ability and reduce the non-target activity through the appropriate modification; the siRNA and the conjugate thereof are expected to be applied to prevention and treatment of diseases such as cerebral amyloid vascular disease (CAA), early onset familial Alzheimer's disease (EOFAD) or Alzheimer's disease (AD) which are related to APP targets clinically.
BOPI
Sede Electrónica
